Can a smartphone app help track MS? new study aims to find out
NCT ID NCT05949580
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 39 times
Summary
This study is testing a digital platform that combines brain scan analysis with a patient app and a doctor web portal to monitor relapsing-remitting multiple sclerosis (MS). About 500 participants will use the platform for two years. The goal is to see if doctors and patients find it easy to use and helpful for tracking the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
Jersey Shore University Medical Centre
RECRUITINGNeptune City, New Jersey, 07753, United States
-
Minneapolis Clinic of Neurology
RECRUITINGGolden Valley, Minnesota, 55422, United States
-
Praxis Dr. med. Max Deist und Michael Ernst ?Sinsheim
RECRUITINGSinsheim, 74889, Germany
-
Universitaetsklinikum Carl Gustav Carus an der TU Dresden
RECRUITINGDresden, 01307, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MS Care Platform (icobrain ms and icompanion ms)
What this could lead to
If successful, this could show that digital tools help doctors monitor MS more easily and catch changes earlier, improving care without extra clinic visits.
What could go wrong
This is an early usability study, not testing a treatment. It only measures satisfaction and ease of use, not health outcomes. Results may not change how MS is managed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.